Chronic kidney disease (CKD) affects over 14% of adults in the U.S. and was the ninth-leading cause of death globally in 2023. For decades, treatment options were limited and only modestly effective. However, recent advancements in pharmacology—particularly drugs originally developed for diabetes, obesity, and cardiovascular disease—are now revolutionizing kidney care, raising the possibility of not just slowing, but potentially reversing kidney deterioration.
The Evolution of Kidney Disease Treatment
Until recently, renin-angiotensin system (RAS) inhibitors were the only class of drugs proven to slow CKD progression. While helpful, they were far from a cure. Researchers theorized that drugs addressing related conditions—like diabetes and heart disease—might also benefit kidney health. This led to the investigation of GLP-1 receptor agonists (like Ozempic), mineralocorticoid receptor antagonists (MRAs) such as finerenone, and SGLT2 inhibitors as potential treatments.
The Rise of SGLT2 Inhibitors and Beyond
The turning point came in 2019 with trials of SGLT2 inhibitors, initially used for type 2 diabetes. These drugs proved effective not only in lowering blood glucose but also in preserving kidney function. Subsequent studies confirmed these benefits even in patients without diabetes, showing reductions in creatinine levels, cardiovascular events, and the need for dialysis or transplants. The combination of SGLT2 inhibitors with RAS inhibitors has been shown to cut kidney disease progression by about 30%, potentially adding over 20 years to the lifespan of a patient’s kidneys.
The next major breakthrough was finerenone, an MRA, which demonstrated improved cardiovascular outcomes and reduced kidney disease progression in trials. Crucially, finerenone’s mechanism differs from both SGLT2 inhibitors and GLP-1 receptor agonists, making combination therapies even more promising. Recent studies indicate that combining finerenone with an SGLT2 inhibitor yields additive benefits: roughly double the effectiveness of either drug alone.
The Potential of GLP-1 Receptor Agonists
Finally, GLP-1 receptor agonists (Ozempic, Wegovy) originally designed for diabetes and obesity, have shown potential in kidney care. Trials confirm that semaglutide reduces kidney failure, renal death, and the need for transplants, even in non-diabetic patients. These drugs appear to work through multiple mechanisms, including weight loss, blood pressure control, reduced inflammation, and potentially direct effects on kidney blood vessels.
The Future of Kidney Disease Treatment
Researchers are now exploring optimal drug combinations—including RAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and MRAs. The World Health Organization has recognized CKD as a major public health priority. The next step is increased awareness, broader screening, and ensuring equitable access to these life-changing medications.
“We need to up our game. Instead of just hoping to stop kidney disease progression, we need to try to reverse the process.” —Maarten Taal, University of Nottingham
The emerging evidence suggests that reversing kidney damage is biologically possible. While further trials are needed to confirm simultaneous dosing of all four drug classes, the current trajectory points toward a future where kidney disease is not just managed but potentially cured.
